Benjamin Daquioag.
Phone number 713-526-9821 ext217


A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 120 mg for 24 weeks and BI 201335 240 mg for 12 weeks in combination with pegylated interferon-α and ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C infection

Copyright © 2024. Cure C Consortium